NanoMedical Systems develops implantable drug-delivery devices using proprietary nanofluidics technology. Their nstrada platform uses tiny channels in a subcutaneous implant to provide constant, controlled release of various medicines, including small molecules, peptides and proteins, for weeks to over a year without moving parts or power requirements. Unlike older polymer-based implants, the nstrada system avoids burst effects and reaches steady drug levels within days. They would be well-suited to receive referrals from pharmaceutical companies, biotech firms and research organisations developing chronic therapies that need novel delivery methods.